177 related articles for article (PubMed ID: 36678572)
1. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
[TBL] [Abstract][Full Text] [Related]
2. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.
Puleo DE; Kucera K; Hammarén HM; Ungureanu D; Newton AS; Silvennoinen O; Jorgensen WL; Schlessinger J
ACS Med Chem Lett; 2017 Jun; 8(6):618-621. PubMed ID: 28626521
[TBL] [Abstract][Full Text] [Related]
3. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
Liosi ME; Ippolito JA; Henry SP; Krimmer SG; Newton AS; Cutrona KJ; Olivarez RA; Mohanty J; Schlessinger J; Jorgensen WL
J Med Chem; 2022 Jun; 65(12):8380-8400. PubMed ID: 35653642
[TBL] [Abstract][Full Text] [Related]
4. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
5. Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
Liosi ME; Krimmer SG; Newton AS; Dawson TK; Puleo DE; Cutrona KJ; Suzuki Y; Schlessinger J; Jorgensen WL
J Med Chem; 2020 May; 63(10):5324-5340. PubMed ID: 32329617
[TBL] [Abstract][Full Text] [Related]
6. Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.
Henry SP; Liosi ME; Ippolito JA; Cutrona KJ; Krimmer SG; Newton AS; Schlessinger J; Jorgensen WL
ACS Med Chem Lett; 2022 May; 13(5):819-826. PubMed ID: 35586418
[TBL] [Abstract][Full Text] [Related]
7. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
10. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
[TBL] [Abstract][Full Text] [Related]
11. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
12. Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.
Newton AS; Liosi ME; Henry SP; Deiana L; Faver JC; Krimmer SG; Puleo DE; Schlessinger J; Jorgensen WL
Tetrahedron Lett; 2021 Aug; 77():. PubMed ID: 34393283
[TBL] [Abstract][Full Text] [Related]
13. The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.
Sanz Sanz A; Niranjan Y; Hammarén H; Ungureanu D; Ruijtenbeek R; Touw IP; Silvennoinen O; Hilhorst R
Biochim Biophys Acta; 2014 Oct; 1844(10):1835-41. PubMed ID: 25107665
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
15. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
16. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
17. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
18. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
[TBL] [Abstract][Full Text] [Related]
19. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
Raivola J; Haikarainen T; Silvennoinen O
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
[TBL] [Abstract][Full Text] [Related]
20. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
